Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. SEOM guide to antiemetic prophylaxis in cancer patients treated with chemotherapy 2013.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2013
   Guideline
2. Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016
   Trial
3. Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2013
   Trial
4. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2011
   Trial
5. Anti-Emetics in Children Receiving Chemotherapy for Solid Tumors and Leukemia: Pharmacology and Optimization of Therapy for Nausea and Vomiting.Pharmaceuticals (Basel, Switzerland) · 2024
   Review
6. A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study).EClinicalMedicine · 2023
   Article
7. Expert Consensus on Effective Management of Chemotherapy-Induced Nausea and Vomiting: An Indian Perspective.Frontiers in oncology · 2020
   Article
8. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017
   Article
9. Glycemic Status and Infection Risk in Nondiabetic Autologous Hematopoietic Cell Transplantation Recipients.Biological research for nursing · 2016
   Article
10. Response.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2015
    Article
11. Chemotherapy induced nausea and vomiting in bone marrow transplant: the unmet need.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2015
    Article
12. Management of Chemotherapy Induced Nausea and Vomiting in Patients on Multiday Cisplatin Based Combination Chemotherapy.BioMed research international · 2015
    Review
13. Safety and pharmacokinetic evaluation of repeated intravenous administration of palonosetron 0.75 mg in patients receiving highly or moderately emetogenic chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2014
    Article
14. Efficacy and safety of aprepitant in allogeneic hematopoietic stem cell transplantation.Pharmacotherapy · 2013
    Observational
15. Obstacles to managing chemotherapy-induced nausea and vomiting in high-dose chemotherapy with stem cell transplant.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2012
    Article

Corrections and comments

• Commented on by
  Obstacles to managing chemotherapy-induced nausea and vomiting in high-dose chemotherapy with stem cell transplant.2012

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as